TVTX
Travere Therapeutics, Inc. NASDAQ Listed Nov 8, 2012$42.67
Mkt Cap $4.0B
52w Low $13.88
82.9% of range
52w High $48.61
50d MA $33.15
200d MA $29.20
P/E (TTM)
-78.8x
EV/EBITDA
164.0x
P/B
34.3x
Debt/Equity
2.9x
ROE
-22.2%
P/FCF
90.2x
RSI (14)
—
ATR (14)
—
Beta
0.87
50d MA
$33.15
200d MA
$29.20
Avg Volume
1.8M
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
3611 Valley Centre Drive · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.24 | -0.40 | -65.3% | 44.91 | +1.8% | -0.2% | -0.3% | -5.0% | — | — | — |
| Feb 19, 2026 | AMC | 0.03 | 0.03 | +0.0% | 29.30 | +0.6% | +3.7% | +4.9% | +5.4% | +0.1% | +1.4% | — |
| Oct 30, 2025 | AMC | -0.31 | 0.28 | +190.3% | 29.65 | +16.7% | +18.6% | +16.5% | +15.1% | +13.7% | +12.3% | — |
| Aug 6, 2025 | AMC | -0.28 | -0.14 | +50.0% | 17.24 | +1.0% | -1.9% | -1.7% | +0.2% | +1.0% | +4.7% | — |
| May 1, 2025 | AMC | -0.55 | -0.47 | +14.5% | 20.76 | +1.6% | +1.9% | +3.1% | -3.9% | -2.6% | -1.5% | — |
| Feb 20, 2025 | AMC | -0.58 | -0.73 | -25.9% | 23.58 | -8.8% | -6.8% | -10.0% | -12.4% | -10.8% | -12.5% | — |
| Oct 31, 2024 | AMC | -0.70 | -0.70 | +0.0% | 17.50 | +2.6% | +0.4% | +3.4% | +1.4% | -1.1% | +0.9% | — |
| Aug 1, 2024 | AMC | -0.87 | -0.90 | -3.4% | 9.24 | +8.4% | -2.6% | -7.7% | -3.7% | -8.9% | -7.7% | — |
| May 6, 2024 | AMC | -0.98 | -1.76 | -79.6% | 6.55 | +13.0% | +3.1% | +4.1% | +0.8% | -3.8% | -3.2% | — |
| Feb 15, 2024 | AMC | -1.27 | -1.16 | +8.7% | 8.74 | +0.7% | -6.2% | -5.3% | -9.8% | -10.1% | -9.2% | — |
| Nov 7, 2023 | AMC | -1.09 | -1.17 | -7.3% | 7.18 | +0.7% | -11.8% | -24.2% | -22.3% | -20.6% | -15.2% | — |
| Aug 3, 2023 | AMC | -1.16 | -1.13 | +2.6% | 16.28 | -4.0% | -4.7% | -5.5% | -4.8% | -6.3% | -3.7% | — |
| May 4, 2023 | AMC | -1.18 | -1.27 | -7.6% | 15.97 | +0.1% | +5.2% | +4.8% | +3.8% | +1.9% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Guggenheim | Maintains | Buy → Buy | — | $40.82 | $41.35 | +1.3% | -0.8% | -0.0% | +0.2% | -1.8% | +3.2% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | +33.4% | +28.8% | +32.8% | +31.2% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | +33.4% | +28.8% | +32.8% | +31.2% |
| Apr 14 | Citigroup | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | +33.4% | +28.8% | +32.8% | +31.2% |
| Apr 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | +33.4% | +28.8% | +32.8% | +31.2% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $30.70 | $41.53 | +35.3% | +37.2% | +33.4% | +28.8% | +32.8% | +31.2% |
| Mar 25 | JP Morgan | Maintains | Overweight → Overweight | — | $26.79 | $26.84 | +0.2% | +2.9% | +4.2% | +1.7% | +3.2% | +10.9% |
| Feb 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $29.47 | $29.91 | +1.5% | +0.8% | +2.0% | +2.9% | +2.5% | +3.8% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.26 | $36.87 | +1.7% | -2.3% | -3.0% | -6.3% | -3.9% | -2.6% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $34.53 | $33.99 | -1.6% | -1.2% | -2.3% | -3.6% | -6.3% | -0.4% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $29.65 | $34.60 | +16.7% | +18.6% | +16.5% | +15.1% | +13.7% | +12.3% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.19 | $24.34 | +0.6% | +2.7% | +5.1% | +0.2% | +0.9% | +1.7% |
| Sep 12 | Stifel | Maintains | Hold → Hold | — | $25.00 | $24.77 | -0.9% | -6.1% | -8.0% | -8.9% | -5.4% | -3.2% |
| Sep 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $27.31 | $27.71 | +1.5% | -8.5% | -14.1% | -15.7% | -16.6% | -13.4% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.64 | $25.31 | +17.0% | +26.2% | +15.5% | +8.5% | +6.3% | +5.2% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.15 | $18.20 | +0.3% | +8.0% | +16.5% | +19.2% | +16.8% | +19.2% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.44 | $19.30 | +10.7% | +1.5% | +0.3% | +4.1% | +12.4% | +21.3% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $17.24 | $17.41 | +1.0% | -1.9% | -1.7% | +0.2% | +1.0% | +4.7% |
| Aug 7 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $17.24 | $17.41 | +1.0% | -1.9% | -1.7% | +0.2% | +1.0% | +4.7% |
| Jun 11 | Citigroup | Maintains | Buy → Buy | — | $15.13 | $15.31 | +1.2% | -4.0% | -1.3% | -4.2% | -3.0% | -6.9% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $21.15 | $18.01 | -14.8% | -20.6% | -19.6% | -17.0% | -21.5% | -25.8% |
| May 2 | Wedbush | Maintains | Outperform → Outperform | — | $20.76 | $21.09 | +1.6% | +1.9% | +3.1% | -3.9% | -2.6% | -1.5% |
| May 2 | Stifel | Maintains | Hold → Hold | — | $20.76 | $21.09 | +1.6% | +1.9% | +3.1% | -3.9% | -2.6% | -1.5% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.88 | $16.23 | +2.2% | +5.2% | +11.0% | +15.4% | +21.9% | +26.4% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $14.50 | $14.95 | +3.1% | +2.3% | +2.8% | +0.5% | +2.9% | +4.2% |
| Apr 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.35 | $14.50 | +1.0% | -6.0% | +1.0% | +3.3% | +3.9% | +1.5% |
| Apr 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.94 | $16.65 | -7.2% | -7.7% | -16.4% | -15.4% | -21.1% | -20.0% |
| Apr 1 | BofA Securities | Maintains | Buy → Buy | — | $17.92 | $18.16 | +1.3% | -2.7% | +0.1% | -7.6% | -16.4% | -15.3% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $20.65 | $21.17 | +2.5% | +1.8% | -0.0% | +3.6% | -4.1% | -4.6% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $21.98 | $22.06 | +0.4% | -3.4% | -6.1% | -4.3% | -6.1% | -2.6% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.58 | $21.50 | -8.8% | -6.8% | -10.0% | -12.4% | -10.8% | -12.5% |
| Feb 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $23.75 | $23.53 | -0.9% | -2.3% | -0.1% | -3.5% | -4.6% | -1.8% |
| Feb 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $23.75 | $23.53 | -0.9% | -2.3% | -0.1% | -3.5% | -4.6% | -1.8% |
| Feb 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $23.75 | $23.53 | -0.9% | -2.3% | -0.1% | -3.5% | -4.6% | -1.8% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.07 | $17.54 | +2.8% | +5.9% | +8.2% | +7.6% | +14.0% | +14.0% |
| Nov 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.56 | $18.65 | +0.5% | -0.5% | -4.5% | -6.3% | -6.3% | -3.8% |
| Nov 1 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $17.50 | $17.95 | +2.6% | +0.4% | +3.4% | +1.4% | -1.1% | +0.9% |
| Nov 1 | Barclays | Maintains | Overweight → Overweight | — | $17.50 | $17.95 | +2.6% | +0.4% | +3.4% | +1.4% | -1.1% | +0.9% |
| Oct 21 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $17.87 | $19.12 | +7.0% | +1.3% | +0.6% | +0.5% | +1.2% | -1.9% |
| Oct 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $17.11 | $17.05 | -0.4% | -4.1% | +1.9% | +3.4% | +5.5% | +6.7% |
| Oct 9 | BofA Securities | Maintains | Buy → Buy | — | $15.21 | $15.65 | +2.9% | +15.6% | +12.5% | +7.9% | +14.7% | +16.3% |
| Oct 9 | Wedbush | Maintains | Outperform → Outperform | — | $15.21 | $15.65 | +2.9% | +15.6% | +12.5% | +7.9% | +14.7% | +16.3% |
| Oct 9 | Guggenheim | Maintains | Buy → Buy | — | $15.21 | $15.65 | +2.9% | +15.6% | +12.5% | +7.9% | +14.7% | +16.3% |
| Oct 8 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.26 | $15.31 | +0.3% | -0.3% | +15.3% | +12.1% | +7.5% | +14.3% |
| Oct 1 | Barclays | Maintains | Overweight → Overweight | — | $13.99 | $13.74 | -1.8% | +0.0% | -0.9% | -2.4% | +8.9% | +9.1% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.01 | $14.30 | +2.1% | -0.1% | -0.1% | -1.0% | -2.6% | +8.7% |
| Sep 27 | BofA Securities | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -7.0% | -7.0% | -7.8% | -9.2% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -7.0% | -7.0% | -7.8% | -9.2% |
| Sep 27 | Guggenheim | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -7.0% | -7.0% | -7.8% | -9.2% |
| Sep 27 | Citigroup | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -7.0% | -7.0% | -7.8% | -9.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 2,763 | $43.95 | $121K | 115,474 | -4.69% | — |
| May 6, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 311 | $43.95 | $14K | 113,238 | -4.69% | — |
| May 6, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2,076 | $43.95 | $91K | 105,211 | -4.69% | — |
| May 6, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 22,500 | $43.95 | $989K | 432,886 | -4.69% | — |
| May 6, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 310 | $43.95 | $14K | 118,658 | -4.69% | — |
| May 5, 2026 | Baynes Roy D. | — | Sell | 4,500 | $46.65 | $210K | 37,500 | -4.69% | — |
| May 5, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2,174 | $46.65 | $101K | 113,549 | -4.69% | — |
| May 5, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2,174 | $46.65 | $101K | 107,287 | -4.69% | — |
| May 5, 2026 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $46.65 | $101K | 140,684 | -4.69% | — |
| May 5, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2,181 | $46.65 | $102K | 118,968 | -4.69% | — |
| May 4, 2026 | Meckler Jeffrey A | — | Sell | 8,000 | $45.00 | $360K | 87,500 | -4.69% | — |
| May 4, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 20,000 | $45.00 | $900K | 111,473 | -4.69% | — |
| May 4, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 20,000 | $45.00 | $900K | 105,211 | -4.69% | — |
| May 1, 2026 | Baynes Roy D. | — | Sell | 9,750 | $44.22 | $431K | 37,500 | -0.24% | — |
8-K · 2.02
!! High
Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Travere Therapeutics reported earnings results, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 4
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TVTX's FILSPARI demonstrated superior efficacy in reducing proteinuria (48% vs 27%) in IgA nephropathy patients, validating its lead program and strengthening approval prospects for this high-value kidney disease indication.
Apr 14
8-K
Travere Therapeutics, Inc. -- 8-K Filing
Travere Therapeutics' FILSPARI achieved $103 million in Q4 2025 net sales with 108% year-over-year growth and 908 new patient starts, demonstrating strong market adoption for this rare disease treatment.
Feb 19
Data updated apr 27, 2026 6:09am
· Source: massive.com